



IFW

Docket No.: 278283US0X PCT

COMMISSIONER FOR PATENTS
ALEXANDRIA, VIRGINIA 22313



RE: Application Serial No.: 10/550,414
Applicants: Ryuji UENO, et al.
Filing Date: September 23, 2005
For: METHOD FOR TREATING VASCULAR
HYPERPERMEABLE DISEASE
Group Art Unit: 1617
Examiner: RAMACHANDRAN, U.

SIR:

Attached hereto for filing are the following papers:

Response to Restriction Requirement

Our check in the amount of \$0.00 is attached covering any required fees. In the event any variance exists between the amount enclosed and the Patent Office charges for filing the above-noted documents, including any fees required under 37 C.F.R. 1.136 for any necessary Extension of Time to make the filing of the attached documents timely, please charge or credit the difference to our Deposit Account No. 15-0030. Further, if these papers are not considered timely filed, then a petition is hereby made under 37 C.F.R. 1.136 for the necessary extension of time. A duplicate copy of this sheet is enclosed.

Respectfully submitted,

OBLON, SPIVAK, McCLELLAND,
MAIER & NEUSTADT, P.C.
Norman F. Oblon

James H. Knebel

Registration No. 22,630


John Niebling
Registration No. 57,981

Customer Number

22850

(703) 413-3000 (phone)
(703) 413-2220 (fax)



DOCKET NO: 278283US0X PCT

IN THE UNITED STATES PATENT & TRADEMARK OFFICE

IN RE APPLICATION OF :
RYUJI UENO, ET AL. : EXAMINER: RAMACHANDRAN, U.
SERIAL NO: 10/550,414 :
FILED: SEPTEMBER 23, 2005 : GROUP ART UNIT: 1617
FOR: METHOD FOR TREATING :
VASCULAR HYPERPERMEABLE
DISEASE

RESPONSE TO RESTRICTION REQUIREMENT

COMMISSIONER FOR PATENTS
ALEXANDRIA, VIRGINIA 22313

SIR:

In response to the Restriction Requirement mailed November 1, 2006, Applicants elect, with traverse, Group II, Claims 1-10, and further elect the compound N-{4-[2-(4-{[amino(imino)methyl]amino}phenyl)ethyl]-5-[4-(methylsulfonyl)benzyl]-1,3-thiazol-2-yl}acetamide as a single species from Claims 5, 6 and 7. In addition, Applicants elect diabetic retinopathy as the single species of diseases listed in Claim 4.

Applicants respectfully submit that, should the claims of Group II be found allowable, the Office should expand its search to the claims of Group I as they pertain to VAP-1/inhibitor compounds wherein Z is 1H-benzoimidiazol-2-amine.

Remarks/Arguments begin on page 2 of this paper.